Now open: Broad Agency Announcements
Now open: Broad Agency Announcements for Advanced Research and
Development of Medical Countermeasures for Pandemic Influenza and
Chemical, Biological, Radiological and Nuclear Threats
BARDA is soliciting proposals for the advanced research and
development of medical countermeasures (MCM) such as vaccines,
therapeutics, diagnostics and devices. Specifics of the
solicitation can be found under three Broad Agency Announcements
(BAA), renewed today, which aim to develop MCMs for and support
capabilities to address multiple public health threats. The BAAs
are:
- BARDA-CBRN-BAA-12-100-SOL-00011 aims to
develop MCMs for chemical, biological, radiological, and nuclear
(CBRN) agents.
- BARDA-BAA-12-100-SOL-00018 will support
development of MCMs for pandemic influenza.
-BARDA-BAA-12-100-SOL-00013 will support
innovation through development of platform technologies that
enhance capabilities for development and manufacturing of
MCMs.
BARDA is working to build a pipeline of candidate medical
countermeasures to support the preparedness mission of the Public
Health Emergency Medical Countermeasures Enterprise (PHEMCE).
Funding through these BAAs will be evaluated with respect to their
relevance to medical countermeasure priorities as laid out in the
2007 PHEMCE Implementation Plan for CBRN
Threats, the National Strategy for Pandemic Influenza, the
2010 HHS Public Health Emergency Medical
Countermeasures Enterprise Review, and the BARDA Strategic Plan 2011-2016.
BARDA anticipates that advanced research and development contracts
awarded under these BAAs will advance the maturity and scientific
understanding of candidate medical countermeasures, and result in a
broader portfolio of products for potential consideration under
future procurement activities.
###